[CAS NO. 152121-30-7] SB 202190

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [152121-30-7]

Catalog

HY-10295

Brand

MCE

CAS

152121-30-7

DESCRIPTION [152121-30-7]

Overview

MDL	MFCD00941964
Molecular Weight	331.34
Molecular Formula	C20H14FN3O
SMILES	FC1=CC=C(C2=C(C3=CC=NC=C3)NC(C4=CC=C(O)C=C4)=N2)C=C1

For research use only. We do not sell to patients.

57 Publications Citing Use of MCE

Summary

SB 202190 is a selective p38 MAP kinase inhibitor with IC ₅₀ s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a K _d of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits ^[1] ^[2] . SB202190 induces autophagy ^[3] .

IC50 & Target

p38α

50 nM (IC ₅₀ )

p38β2

100 nM (IC ₅₀ )

In Vitro

SB 202190 (0-10 μM; 0-72 hours) attenuates growth of a subgroup of CRC cell lines such as RKO, CACO2 and SW480 in a dose- and time-dependent manner ^[1] .
SB 202190 strongly inhibited colony formation and anchorage-independent growth (10 μM for 7–10 days) and elevated apoptotic cell death (10 μM for 72 h) in this same subset of CRC lines (RKO, CACO2 and SW480) ^[2] .
In RKO, CACO2 and SW480 cells, SB202190 (10 μM; 2 hours) abrogates phosphorylation of S6K1(T389) and S6(S235/236), but not AKT(S473), indicating that p38i selectively blocks mTORC1 signaling ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SB 202190 (5 mg/kg; intraperitoneal injection; daily for 10-12 days) shows inhibition of tumor cell survival and tumor growth ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4-week-old female BALB/c nude mice (bearing SW480 and RKO xenograft tumors) ^[2]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; daily for 10-12 days
Result:	Inhibition of tumor cell survival and tumor growth.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 301.80 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0180 mL	15.0902 mL	30.1805 mL
5 mM	0.6036 mL	3.0180 mL	6.0361 mL
10 mM	0.3018 mL	1.5090 mL	3.0180 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (6.28 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (6.28 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (6.28 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Phenol, 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-

4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol

SB 202190

4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole